



|                                                       |                                              |                                             |                    |                  |
|-------------------------------------------------------|----------------------------------------------|---------------------------------------------|--------------------|------------------|
| Patient ID<br><b>SA00123431</b>                       | Patient Name<br><b>TESTING, ABNORMALBPAB</b> | Birth Date<br><b>1984-10-10</b>             | Gender<br><b>M</b> | Age<br><b>35</b> |
| Order Number<br><b>SA00123431</b>                     | Client Order Number<br><b>SA00123431</b>     | Ordering Physician<br><b>CLIENT, CLIENT</b> | Report Notes       |                  |
| Account Information<br><b>C7028846 DLMP Rochester</b> |                                              | Collected<br><b>10 Oct 2019 04:00</b>       |                    |                  |

## BP 180 and 230, Serum

### BP 180, S



**60 RU/mL**

High

The BP180 and BP230 ELISA tests are intended for in vitro use as an aid in the diagnosis of pemphigoid and related entities. Positive test results could be compatible with a diagnosis of pemphigoid. However, final clinical diagnosis should be based on integration of clinical features and results of other supportive tests, such as histopathology on standard microscopy, perilesional biopsy for direct immunofluorescence (test code CIB), and indirect immunofluorescence on human salt-split skin and monkey esophagus substrates (test code CIFS).

MCR

Reference Value  
<20

related entities. Positive test results could be compatible with a diagnosis of pemphigoid. However, final clinical diagnosis should be based on integration of clinical features and results of other supportive tests, such as histopathology on standard microscopy, perilesional biopsy for direct immunofluorescence (test code CIB), and indirect immunofluorescence on human salt-split skin and monkey esophagus substrates (test code CIFS).

#### ADDITIONAL INFORMATION

BP180 and BP230 are intended for in vitro diagnostic use as an aid in the diagnosis of pemphigoid and related entities, and should be interpreted in conjunction with other laboratory and clinical findings.

Received: 14 Oct 2019 12:02

Reported: 14 Oct 2019 12:14

### BP 230, S



**60 RU/mL**

High

The BP180 and BP230 ELISA tests are intended for in vitro use as an aid in the diagnosis of pemphigoid and

1 MCR

Reference Value  
<20

### Laboratory Notes

- 1 This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

### Performing Site Legend

| Code | Laboratory                                       | Address                                  | Lab Director                | CLIA Certificate |
|------|--------------------------------------------------|------------------------------------------|-----------------------------|------------------|
| MCR  | Mayo Clinic Laboratories - Rochester Main Campus | 200 First Street SW, Rochester, MN 55905 | William G. Morice M.D. Ph.D | 24D0404292       |